<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T13:36:53Z</responseDate><request verb="GetRecord" identifier="oai:uwspace.uwaterloo.ca:10012/5987" metadataPrefix="dim">https://dspacemainprd01.lib.uwaterloo.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:uwspace.uwaterloo.ca:10012/5987</identifier><datestamp>2017-03-21T14:26:38Z</datestamp><setSpec>com_10012_9936</setSpec><setSpec>com_10012_1</setSpec><setSpec>col_10012_9941</setSpec><setSpec>col_10012_6</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author" authority="b94df5ce-31df-49ea-86ed-5888ee8d415e" confidence="600">Johnson, Jarrod William</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2011-05-31T19:44:11Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-07-18T05:00:22Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2011-05-31T19:44:11Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="submitted">2011-05-25</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/10012/5987</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en">Bacterial resistance to antibiotics is an emerging epidemic throughout the world and there is a desperate need for new antibiotics and new strategies to maintain the effectiveness of current agents. β-Lactams, such as the penicillins and cephalosporins, have been the most important class of antibiotic for several decades and represent half of the global antibacterial market, but the continued use of β-lactams is threatened by β-lactamases, enzymes that efficiently inactivate β-lactams through hydrolysis. Class A, C, and D β-lactamases use an active-site serine residue for hydrolysis and achieve turnover through an acylenzyme intermediate while the class B metallo-β-lactamases (MBLs) use a zinc-bound hydroxide as the active-site nucleophile.&#xd;
Two successful approaches to combat β-lactamase-mediated resistance have involved the development of β-lactam antibiotics which bind poorly to β-lactamases and the combination of β-lactams with β-lactamase inhibitors. These strategies have been effective for overcoming resistance due to class A β-lactamases, but the ever-increasing prevalence of extended-spectrum β-lactamases (ESBLs), metallo-β-lactamases, and carbapenemases compromises the effectiveness of current penicillins, cephalosporins, carbapenems, and mechanism-based β-lactamase inhibitors. &#xd;
Cyclobutanone analogues of β-lactam antibiotics were explored in the early 1980s as potential inhibitors of β-lactamases and D-Ala-D-Ala transpeptidases, but simple analogues showed only weak inhibitory activity and this approach was subsequently abandoned. The increasing threat of multidrug-resistant β-lactamase-producing organisms in recent years, however, has inspired a re-evaluation of these inhibitors since cyclobutanones have the potential to exhibit broad-spectrum inhibition of both serine- and metallo-β-lactamases through the formation of enzyme-bound hemiketals or hydrates. &#xd;
7,7-Dichloro-2-thia-bicyclo[3.2.0]heptan-6-one-4-carboxylic acid (65), a dichlorocyclobutanone that had shown modest inhibition of the class B and D β-lactamases IMP-1 and OXA-10 in earlier work in this laboratory, was prepared in an efficient seven-step sequence from triethyl phosphonoacetate (103) with an overall yield of 28%. Initial efforts to improve upon the potency of the cyclobutanones involved functionalization at C3 and a highly stereoselective chlorination with sulfuryl chloride provided the 3α-chloro derivative 117α in nearly quantitative yield. Elimination of HCl from 117α was achieved under a variety of conditions and 3-alkoxy derivatives were prepared from 117α through diastereoselective substitution reactions with alcohols. Cyclobutanones with 3β-OR substituents were found to favour an endo envelope conformation while the 3α-OR derivatives adopt the exo envelope conformation. Evidence from X-ray crystal structures and ab initio molecular orbital calculations suggests that an anomeric effect contributes to the large conformational preference of the tetrahydrothiophene ring that favours the 3-alkoxy substituent in an axial orientation. In addition, the conformation of the bicyclic system was found to have a dramatic effect on the tendency of the cyclobutanone to undergo hemiketal formation. &#xd;
Cyclobutanone analogues of penicillins, including 3-alkoxy derivatives, and cyclobutanone analogues of penems were evaluated against class A, B, C, and D β-lactamases and found to be moderate inhibitors of KPC-2, IMP-1, GC1, and OXA-10. The cyclobutanones found to be most potent were those which are hydrated to a larger extent in aqueous solution. Dichlorocyclobutanones were found to be better inhibitors than dechlorinated cyclobutanones and a 3α-methoxy derivative 152α, which favours the exo envelope conformation in which the C4 carboxylate is equatorial, was found to be a better inhibitor than cyclobutanones that favour the endo envelope conformation. A 3,4-unsaturated penem analogue, 153, showed comparable potency to that of 152α and molecular models of enzyme-inhibitor complexes indicate that an equatorial carboxylate is required for binding to β-lactamases. An X-ray crystal structure of 152α bound to the class D β-lactamase OXA-10 confirms that a serine hemiketal is formed in the active site and that the inhibitor adopts the exo envelope. &#xd;
The biochemical data described above demonstrate that cyclobutanones can indeed act as inhibitors of serine- and metallo-β-lactamases and these cyclobutanones represent the first class of reversible inhibitors to show moderate inhibition of all four classes of β-lactamase. Although the inhibitory potency of these compounds is modest (low micromolar IC50 values), penem analogue 153 was able to enhance the potency of meropenem against carbapenem-resistant MBL-producing clinical isolates of Chryseobacterium meningosepticum and Stenotrophomonas maltophilia and the synergy demonstrated in these antimicrobial assays is encouraging. &#xd;
Synthetic studies toward other C3-alkyl and C3-thioalkyl-substituted inhibitors are described and the design and synthesis of C7-monochloro- and 7α-hydroxymethyl-7β-chloro cyclobutanone derivatives is presented.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="embargoterms" lang="en">1 year</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en">en</dim:field>
   <dim:field mdschema="dc" element="publisher" lang="en">University of Waterloo</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Cyclobutanone</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">β-Lactam</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">β-Lactamase</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Penicillin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Antibacterial</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Antibiotic</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Carbapenem</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Penem</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Cephalosporin</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Ketone</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Inhibition</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Inhibitor</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Serine</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en">Resistance</dim:field>
   <dim:field mdschema="dc" element="subject" qualifier="program" lang="en">Chemistry</dim:field>
   <dim:field mdschema="dc" element="title" lang="en">Cyclobutanone Analogues of β-Lactam Antibiotics as Inhibitors of Serine- and Metallo-β-Lactamases</dim:field>
   <dim:field mdschema="dc" element="type" lang="en">Doctoral Thesis</dim:field>
   <dim:field mdschema="dc" element="comment" qualifier="hidden" lang="en">Though not required by the American Chemical Society, I have obtained permission from the ACS to re-use published material for this thesis.</dim:field>
   <dim:field mdschema="dc" element="pending" lang="en">true</dim:field>
   <dim:field mdschema="uws-etd" element="degree" qualifier="department" lang="en">Chemistry</dim:field>
   <dim:field mdschema="uws-etd" element="degree" lang="en">Doctor of Philosophy</dim:field>
   <dim:field mdschema="uws" element="typeOfResource" lang="en">Text</dim:field>
   <dim:field mdschema="uws" element="peerReviewStatus" lang="en">Unreviewed</dim:field>
   <dim:field mdschema="uws" element="scholarLevel" lang="en">Graduate</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>